Lab
X-Cell Laboratories of Western New York INC
X-Cell Laboratories of Western New York INC was paid $4.74M by Medicaid between Jan 2018 and Dec 2024, across 37 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 31% of everything it billed.
33Billing provider infoX-CELL LABORATORIES OF WESTERN NEW YORK INC
AMHERST, NY 14228
AMHERST, NY 14228
33aNPI1326071424assigned 07/09/2006
33bProvider typeClinical Medical Laboratory
28Total paid$4.74M
24GClaims215,519
24DCodes billed37
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in New York
Rank by total paid#30 of 116
Median peer was paid$618K
This provider vs. median7.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,005 | $415K | |
| 2019 | 20,311 | $467K | |
| 2020 | 27,137 | $569K | |
| 2021 | 41,898 | $887K | |
| 2022 | 42,379 | $961K | |
| 2023 | 39,634 | $878K | |
| 2024incomplete | 26,155 | $563K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 31% | 22,457 | 22,234 | $1.45M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 17% | 35,294 | 35,234 | $808K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 12% | 25,503 | 25,455 | $549K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 8.4% | 23,000 | 22,803 | $398K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 8.4% | 22,995 | 22,800 | $397K |
| 88342 | 3.9% | 5,634 | 5,611 | $187K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 3.0% | 8,356 | 8,281 | $141K |
| 88141 | 2.7% | 18,611 | 18,577 | $127K | |
| 87660 | 1.6% | 6,677 | 6,566 | $78K | |
| 87480 | 1.6% | 6,732 | 6,622 | $76K | |
| 87510 | 1.6% | 6,675 | 6,564 | $76K | |
| 87625 | 1.4% | 2,995 | 2,986 | $64K |
25 more codes
| 88142 | 1.2% | 3,527 | $57K | |
| 88173 | 1.0% | 1,171 | $48K | |
| 87800 | <1% | 2,236 | $46K | |
| 88304 | <1% | 1,868 | $40K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,101 | $38K |
| 88313 | <1% | 3,480 | $30K | |
| 88341 | <1% | 315 | $25K | |
| 87070 | <1% | 3,014 | $20K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,764 | $17K |
| 88360 | <1% | 254 | $15K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 414 | $14K |
| 81001 | <1% | 2,669 | $8K | |
| 87077 | <1% | 973 | $7K | |
| 87186 | <1% | 1,228 | $7K | |
| 87481 | <1% | 274 | $5K | |
| 87081 | <1% | 914 | $4K | |
| 88185 | <1% | 13 | $3K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 60 | $1K |
| 80349 | <1% | 162 | $784.21 | |
| 88172 | <1% | 65 | $626.38 | |
| 87106 | <1% | 38 | $318.68 | |
| 88189 | <1% | 13 | $289.68 | |
| 88184 | <1% | 13 | $223.71 | |
| 87255 | <1% | 12 | $54.66 | |
| 88300 | <1% | 12 | $7.92 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSATCHIDANAND, SATEESH (MEDICAL DIRECTOR)